CY1124609T1 - Υγρη συνθεση ανθρωπινου ινωδογονου - Google Patents
Υγρη συνθεση ανθρωπινου ινωδογονουInfo
- Publication number
- CY1124609T1 CY1124609T1 CY20211100606T CY211100606T CY1124609T1 CY 1124609 T1 CY1124609 T1 CY 1124609T1 CY 20211100606 T CY20211100606 T CY 20211100606T CY 211100606 T CY211100606 T CY 211100606T CY 1124609 T1 CY1124609 T1 CY 1124609T1
- Authority
- CY
- Cyprus
- Prior art keywords
- liquid composition
- fibrogen
- human
- human fibrogen
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η εφεύρεση προτείνει μια φαρμακευτική σύνθεση η οποία εμπεριέχει μεταξύ 10 και 30g/L ινωδογόνο, μεταξύ 10 και 300 mM αργινίνη και μεταξύ 10 και 300 mM γλουταμάτη. Το pΗ της σύνθεσης εμπεριέχεται επιπλέον μεταξύ 6 και 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1663181A FR3061020B1 (fr) | 2016-12-22 | 2016-12-22 | Composition de fibrinogene humain |
PCT/FR2017/053839 WO2018115800A1 (fr) | 2016-12-22 | 2017-12-22 | Composition liquide de fibrinogene humain |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124609T1 true CY1124609T1 (el) | 2022-07-22 |
Family
ID=58358663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100606T CY1124609T1 (el) | 2016-12-22 | 2021-07-06 | Υγρη συνθεση ανθρωπινου ινωδογονου |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200093896A1 (el) |
EP (1) | EP3558381B1 (el) |
CN (2) | CN110087689B (el) |
CY (1) | CY1124609T1 (el) |
DK (1) | DK3558381T3 (el) |
ES (1) | ES2877848T3 (el) |
FR (1) | FR3061020B1 (el) |
HR (1) | HRP20210984T1 (el) |
HU (1) | HUE055246T2 (el) |
LT (1) | LT3558381T (el) |
MX (2) | MX2019007608A (el) |
PL (1) | PL3558381T3 (el) |
PT (1) | PT3558381T (el) |
RS (1) | RS62103B1 (el) |
SI (1) | SI3558381T1 (el) |
WO (1) | WO2018115800A1 (el) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12030918B2 (en) * | 2019-12-06 | 2024-07-09 | University Of Wyoming | Fibrin particles and methods of forming fibrin particles |
EP4384143A1 (en) | 2021-08-13 | 2024-06-19 | Biotest AG | Fibrinogen compositions and methods of preparation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE336207C (de) | 1916-03-05 | 1921-04-28 | Siemens & Halske Akt Ges | Vermittlungsvorrichtung fuer Fernsprechleitungen |
ES2262340T3 (es) | 1998-09-24 | 2006-11-16 | Pharming Intellectual Property Bv | Purificacion del fibrinogeno de la leche mediante el uso de cromatografia de intercambio cationico. |
ES2267289T3 (es) | 1998-09-24 | 2007-03-01 | Pharming Intellectual Property Bv | Purificacion de fibrinogeno a partir de fluidos mediante precipitacion y cromatografia de interaccion hidrofoba. |
DE10261126A1 (de) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
WO2008117746A1 (ja) * | 2007-03-22 | 2008-10-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 固体状フィブリノゲン製剤 |
EP3225252A1 (en) * | 2008-05-02 | 2017-10-04 | Laboratoire Français du Fractionnement et des Biotechnologies | Treatment of bleeding with low half-life fibrinogen |
CN101371921B (zh) * | 2008-10-08 | 2013-02-13 | 余美伦 | 一种速溶冻干纤维蛋白原和凝血酶制剂组合物、制备方法及其用途 |
CN102286095B (zh) * | 2011-07-06 | 2013-08-21 | 大田华灿生物科技有限公司 | 纤维蛋白原的制备方法 |
KR101127127B1 (ko) * | 2011-10-27 | 2012-03-21 | 주식회사 녹십자 | 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법 |
FR3018450B1 (fr) | 2014-03-11 | 2016-04-15 | Lab Francais Du Fractionnement | Procede de preparation de proteines plasmatiques humaines |
-
2016
- 2016-12-22 FR FR1663181A patent/FR3061020B1/fr active Active
-
2017
- 2017-12-22 ES ES17837979T patent/ES2877848T3/es active Active
- 2017-12-22 SI SI201730821T patent/SI3558381T1/sl unknown
- 2017-12-22 PL PL17837979T patent/PL3558381T3/pl unknown
- 2017-12-22 RS RS20210796A patent/RS62103B1/sr unknown
- 2017-12-22 HU HUE17837979A patent/HUE055246T2/hu unknown
- 2017-12-22 DK DK17837979.8T patent/DK3558381T3/da active
- 2017-12-22 CN CN201780078234.XA patent/CN110087689B/zh active Active
- 2017-12-22 CN CN202311177586.4A patent/CN117180406A/zh active Pending
- 2017-12-22 LT LTEP17837979.8T patent/LT3558381T/lt unknown
- 2017-12-22 MX MX2019007608A patent/MX2019007608A/es unknown
- 2017-12-22 US US16/471,869 patent/US20200093896A1/en not_active Abandoned
- 2017-12-22 PT PT178379798T patent/PT3558381T/pt unknown
- 2017-12-22 EP EP17837979.8A patent/EP3558381B1/fr active Active
- 2017-12-22 WO PCT/FR2017/053839 patent/WO2018115800A1/fr unknown
-
2019
- 2019-06-21 MX MX2021001361A patent/MX2021001361A/es unknown
-
2021
- 2021-06-23 HR HRP20210984TT patent/HRP20210984T1/hr unknown
- 2021-07-06 CY CY20211100606T patent/CY1124609T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
FR3061020B1 (fr) | 2019-05-17 |
SI3558381T1 (sl) | 2021-11-30 |
PL3558381T3 (pl) | 2021-10-25 |
CN110087689A (zh) | 2019-08-02 |
WO2018115800A1 (fr) | 2018-06-28 |
US20200093896A1 (en) | 2020-03-26 |
PT3558381T (pt) | 2021-07-01 |
MX2019007608A (es) | 2019-08-29 |
CN110087689B (zh) | 2023-09-29 |
LT3558381T (lt) | 2021-08-10 |
ES2877848T3 (es) | 2021-11-17 |
EP3558381A1 (fr) | 2019-10-30 |
FR3061020A1 (fr) | 2018-06-29 |
EP3558381B1 (fr) | 2021-04-07 |
RS62103B1 (sr) | 2021-08-31 |
HRP20210984T1 (hr) | 2021-09-17 |
CN117180406A (zh) | 2023-12-08 |
HUE055246T2 (hu) | 2021-11-29 |
DK3558381T3 (da) | 2021-06-28 |
MX2021001361A (es) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
CY1122994T1 (el) | Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων | |
CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
CY1124609T1 (el) | Υγρη συνθεση ανθρωπινου ινωδογονου | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
CY1121171T1 (el) | Πυρογλουταμικη βορτιοξετινη | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
EA201990915A1 (ru) | Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения | |
EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
CY1123844T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
CY1124706T1 (el) | Συνδυασμοι και χρησεις αυτων | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
CY1126054T1 (el) | Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων | |
CY1122656T1 (el) | Λιπαντικο συμπλοκο για το στομα |